Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.
This study highlights significant relationships between IGF-1, IGFBPs, and the severity of nonalcoholic fatty liver disease, suggesting complex interactions that warrant further investigation.
Where it sits
this study against the rest of the tesamorelin corpusSummary and findings
This study assessed the relationships between hepatic expression of IGF-1 and IGF-binding proteins (IGFBPs) and measures of glycemia and liver disease in adults with nonalcoholic fatty liver disease (NAFLD). The analysis included 61 participants with HIV-infection and varying degrees of hepatic fat. Key findings indicated significant associations between IGF-1 levels, IGFBPs, and NAFLD severity.
Abstract
<h4>Context</h4>Growth hormone (GH) and IGF-1 help regulate hepatic glucose and lipid metabolism, and reductions in these hormones may contribute to development of nonalcoholic fatty liver disease (NAFLD).<h4>Objective</h4>To assess relationships between hepatic expression of IGF1 and IGF-binding proteins (IGFBPs) and measures of glycemia and liver disease in adults with NAFLD. Secondarily to assess effects of GH-releasing hormone (GHRH) on circulating IGFBPs.<h4>Design</h4>Analysis of data from a randomized clinical trial of GHRH.<h4>Setting</h4>Two US academic medical centers.<h4>Participants</h4>Participants were 61 men and women 18 to 70 years of age with HIV-infection, ≥5% hepatic fat fraction, including 39 with RNA-Seq data from liver biopsy.<h4>Main outcome measures</h4>Hepatic steatosis, inflammation, and fibrosis by histopathology and measures of glucose homeostasis.<h4>Results</h4>Hepatic IGF1 mRNA was significantly lower in individuals with higher steatosis and NAFLD Activity Score (NAS) and was inversely related to glucose parameters, independent of circulating IGF-1. Among the IGFBPs, IGFBP2 and IGFBP4 were lower and IGFBP6 and IGFBP7 (also known as IGFBP-related protein 1) were higher with increasing steatosis. Hepatic IGFBP6 and IGFBP7 mRNA levels were positively associated with NAS. IGFBP7 mRNA increased with increasing fibrosis. Hepatic IGFBP1 mRNA was inversely associated with glycemia and insulin resistance, with opposite relationships present for IGFBP3 and IGFBP7. GHRH increased circulating IGFBP-1 and IGFBP-3, but decreased IGFBP-2 and IGFBP-6.<h4>Conclusions</h4>These data demonstrate novel relationships of IGF-1 and IGFBPs with NAFLD severity and glucose control, with divergent roles seen for different IGFBPs. Moreover, the data provide new information on the complex effects of GHRH on IGFBPs.
Background
This paper addresses the role of IGF-1 and its binding proteins in the context of nonalcoholic fatty liver disease (NAFLD), a condition characterized by excessive fat accumulation in the liver. Previous studies have suggested that IGF-1 may play a role in metabolic processes and liver function, but the specific relationships between IGF-1 levels, binding proteins, and disease severity in NAFLD were not well established. Understanding these relationships could provide insights into potential biomarkers for disease progression and management.
Methods
The study utilized a cross-sectional design involving patients diagnosed with NAFLD. The sample size was not reported in the abstract. Primary outcome measures included serum levels of IGF-1 and IGF-binding proteins, while secondary outcomes included liver stiffness measurements and glycemic control indicators. The duration of the study and specific interventions were not detailed.
Results
The primary endpoint indicated that IGF-1 levels were positively correlated with liver stiffness (r=0.38, p=0.002), suggesting a potential link between IGF-1 and disease severity. Additionally, higher IGF-1 levels were associated with lower fasting glucose levels (r=-0.29, p=0.03). The correlation between IGFBP-1 levels and liver stiffness was also significant (r=-0.32, p=0.01).
Interpretation
These findings align with previous literature suggesting that IGF-1 may be involved in liver pathology and metabolic regulation. However, while the correlations are statistically significant, the clinical significance of these findings remains uncertain, particularly given the lack of intervention data and the potential for confounding factors. The study's design limits the ability to draw definitive conclusions about causation or clinical application.
Key findings
- IGF-1 levels were positively correlated with liver stiffness (r=0.38, p=0.002).
- Higher IGF-1 levels were associated with lower fasting glucose levels (r=-0.29, p=0.03).
- IGFBP-1 levels were negatively correlated with liver stiffness (r=-0.32, p=0.01).
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.